Press Release – New York, NY – December 19, 2025 – Sichenzia Ross Ference Carmel LLP announced that it represented Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a biotech company focused on advancing cancer treatments, in its recently priced $4.3 million registered direct offering.
The SRFC team congratulates CEO Geordan Pursglove and the entire Lixte Biotechnology team on the completion of the offering.
The SRFC team was led by partners Ross Carmel and Matthew Siracusa, with associate Gary Eaton.